CancerDrs

Ovarian Cancer clinical trials in Florida

94 actively recruiting ovarian cancer trials at 54 sites across Florida.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 3 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll.

Phase 3 Recruiting Academic/Other

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among prem…

Sponsor: NRG Oncology
NCT ID: NCT05879926
Sites in Florida:
  • AdventHealth Altamonte — Altamonte Springs, Florida
  • Mount Sinai Comprehensive Cancer Center at Aventura — Aventura, Florida
  • UM Sylvester Comprehensive Cancer Center at Aventura — Aventura, Florida
  • Florida Cancer Specialists - Bradenton Cancer Center — Bradenton, Florida
  • Morton Plant Hospital — Clearwater, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

This phase III trial compares the effect of olaparib for one year versus two years, with or without bevacizumab, for the treatment of BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer. Olaparib is a poly…

Sponsor: NRG Oncology
NCT ID: NCT06580314
Sites in Florida:
  • Holy Cross Hospital — Fort Lauderdale, Florida
  • Broward Health Medical Center — Fort Lauderdale, Florida
  • UF Health Cancer Institute - Gainesville — Gainesville, Florida
  • Orlando Health Cancer Institute - Lake Mary — Lake Mary, Florida
  • Health Central — Ocoee, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it dev…

Sponsor: Children's Oncology Group
NCT ID: NCT03067181
Sites in Florida:
  • Broward Health Medical Center — Fort Lauderdale, Florida
  • Golisano Children's Hospital of Southwest Florida — Fort Myers, Florida
  • UF Health Cancer Institute - Gainesville — Gainesville, Florida
  • Memorial Regional Hospital/Joe DiMaggio Children's Hospital — Hollywood, Florida
  • Nemours Children's Clinic-Jacksonville — Jacksonville, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer

This phase III trial compares the effect of giving triptorelin vs no triptorelin in preventing ovarian damage in adolescents and young adults (AYAs) with cancer receiving chemotherapy with an alkylating agents. Alkylating agents are part o…

Sponsor: Children's Oncology Group
NCT ID: NCT06513962
Sites in Florida:
  • Golisano Children's Hospital of Southwest Florida — Fort Myers, Florida
  • UF Health Cancer Institute - Gainesville — Gainesville, Florida
  • Memorial Regional Hospital/Joe DiMaggio Children's Hospital — Hollywood, Florida
  • Nemours Children's Clinic-Jacksonville — Jacksonville, Florida
  • University of Miami Miller School of Medicine-Sylvester Cancer Center — Miami, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

GLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and efficacy of mirvetuximab Soravtansine + Bevacizumab as maintenance therapy in participants with platinum-sensitive ovarian, primary peritoneal or fallo…

Sponsor: AbbVie
NCT ID: NCT05445778
Sites in Florida:
  • Broward General Medical Center /ID# 269577 — Fort Lauderdale, Florida
  • Regional Cancer Center /ID# 269558 — Fort Myers, Florida
  • Baptist Md Anderson Cancer Center - Jacksonville - Palm Avenue /ID# 269560 — Jacksonville, Florida
  • Mount Sinai Medical Center /ID# 269582 — Miami, Florida
  • Sarasota Memorial Hospital /ID# 269526 — Sarasota, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer

Patients will be registered prior to, during or at the completion of neoadjuvant chemotherapy given per standard institutional guidelines +/- bevacizumab on Day 1 every 21 days for 3-4 cycles. Registered patients who progress during neoadj…

Sponsor: GOG Foundation
NCT ID: NCT05659381
Sites in Florida:
  • Sylvester Comprehensive Cancer Center - The Lennar Foundation Medical Center — Coral Gables, Florida
  • University of Miami Hospital and Clinics - Deerfield Beach — Deerfield Beach, Florida
  • University of Miami Hospital and Clinics — Miami, Florida
  • Miami Cancer Institute — Miami, Florida
  • Sylvester Comprehensive Cancer Center - Plantation — Plantation, Florida
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

This study will evaluate the safety and efficacy of R-DXd therapy in participants with ovarian, peritoneal, or fallopian tube cancer.

Sponsor: Daiichi Sankyo
NCT ID: NCT06161025
Sites in Florida:
  • Sylvester Comprehensive Cancer Center at Lennar — Coral Gables, Florida
  • Sylvester Comprehensive Cancer Center at Deerfield Beach — Deerfield Beach, Florida
  • Florida Cancer Specialists — Lake Mary, Florida
  • Sylvester Cancer Center — Miami, Florida
  • Mount Sinai Comprehensive Cancer Center — Miami Beach, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (ICT) in subjects with recurrent LGSOC who have progressed on a prior platinum-based therapy.

Sponsor: Verastem, Inc.
NCT ID: NCT06072781
Sites in Florida:
  • Florida Cancer Specialists - South — Fort Myers, Florida
  • Mount Sinai — Miami Beach, Florida
  • AdventHealth — Orlando, Florida
  • Moffitt Cancer Center — Tampa, Florida
  • Florida Cancer Specialists Research East — West Palm Beach, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

The OnPrime study is a multi-center, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab compared to the Active Comparator Arm with Physician's Choice…

Sponsor: Genelux Corporation
NCT ID: NCT05281471
Sites in Florida:
  • AdventHealth Cancer Institute — Orlando, Florida
  • Sarasota Memorial Research Institute — Sarasota, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

The main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and if people who take sacituzumab tirumotecan with or without bevacizumab live longer without the cancer get…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06824467
Sites in Florida:
  • Mount Sinai Cancer Center ( Site 0078) — Miami Beach, Florida
  • Sarasota Memorial Hospital ( Site 0075) — Sarasota, Florida
  • Florida Cancer Specialists East ( Site 7000) — West Palm Beach, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer

The intention of the study is to demonstrate superiority of AZD5335 versus standard of care by assessment of progression-free survival (PFS) in women with high-grade, platinum-resistant epithelial ovarian, fallopian tube, or primary perito…

Sponsor: AstraZeneca
NCT ID: NCT07218809
Sites in Florida:
  • Research Site — Fort Lauderdale, Florida
  • Research Site — Jupiter, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial

This phase III trial compares minimally invasive surgery (MIS) to laparotomy in treating patients with stage IIIC-IV ovarian, primary peritoneal, or fallopian tube cancer who are receiving chemotherapy before and after surgery (neoadjuvant…

Sponsor: M.D. Anderson Cancer Center
NCT ID: NCT04575935
Sites in Florida:
  • University of Miami Miller School of Medicine-Sylvester Cancer Center — Miami, Florida
  • Cleveland Clinic Foundation - Florida — Weston, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

This is a randomized, adaptive, open label, multicenter trial to evaluate the safety and efficacy of intraperitoneal (IP) IMNN-001 plus chemotherapy compared to chemotherapy alone.

Sponsor: Imunon
NCT ID: NCT06915025
Sites in Florida:
  • Advent Health — Orlando, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

Researchers are looking for new ways to treat ovarian cancer (OC). Current treatment for OC may start with surgery to remove as much of the cancer as possible. After surgery, people may receive chemotherapy. After chemotherapy, standard ca…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT07318558
Sites in Florida:
  • Mount Sinai Cancer Center ( Site 0029) — Miami Beach, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy

This Phase 3 study will be conducted in different countries around the world with up to about 528 participants. The purpose of this study is to evaluate how well Rina-S works against ovarian cancer in combination with available standard of…

Sponsor: Genmab
NCT ID: NCT07225270
Sites in Florida:
  • Mt. Sinai Comprehensive Cancer Center — Miami, Florida
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564377
Sites in Florida:
  • UM Sylvester Comprehensive Cancer Center at Aventura — Aventura, Florida
  • UM Sylvester Comprehensive Cancer Center at Coral Gables — Coral Gables, Florida
  • UM Sylvester Comprehensive Cancer Center at Deerfield Beach — Deerfield Beach, Florida
  • Broward Health Medical Center — Fort Lauderdale, Florida
  • UF Health Cancer Institute - Gainesville — Gainesville, Florida
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

This phase II ComboMATCH treatment trial compares selumetinib plus olaparib to selumetinib alone in women with endometrial or ovarian (fallopian tube and primary peritoneal) cancer that has come back (recurrent) or that remains despite tre…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05554328
Sites in Florida:
  • UM Sylvester Comprehensive Cancer Center at Aventura — Aventura, Florida
  • UM Sylvester Comprehensive Cancer Center at Coral Gables — Coral Gables, Florida
  • UM Sylvester Comprehensive Cancer Center at Deerfield Beach — Deerfield Beach, Florida
  • Mayo Clinic in Florida — Jacksonville, Florida
  • University of Miami Miller School of Medicine-Sylvester Cancer Center — Miami, Florida
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

This is a multi-part Phase 2 study to evaluate the efficacy and safety of azenosertib (ZN-c3) in subjects with Platinum-Resistant, High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. Part 2 of the study will be conduct…

Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
NCT ID: NCT05128825
Sites in Florida:
  • Site 0239 - Florida Cancer Specialists - East — Daytona Beach, Florida
  • Site 0173 - Mount Sinai Medical Center — Miami Beach, Florida
  • Site 0308 - Advent Health — Orlando, Florida
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

This study will evaluate the safety and efficacy of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer (PROC) With Cyclin E1 Overexpression.

Sponsor: Incyte Corporation
NCT ID: NCT07023627
Sites in Florida:
  • Florida Cancer Specialists & Research Institute — Fort Myers, Florida
  • Mayo Clinic — Jacksonville, Florida
  • Sylvester Comprehensive Cancer Center — Miami, Florida
  • Mount Sinai Comprehensive Cancer Center — Miami Beach, Florida
  • Florida Cancer Specialists & Research Institute — West Palm Beach, Florida
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone an…

Sponsor: Artios Pharma Ltd
NCT ID: NCT04657068
Sites in Florida:
  • Florida Cancer Specialists — Fort Myers, Florida
  • Mayo Clinic (Florida) — Jacksonville, Florida
  • Cancer Specialists of North Florida — Jacksonville, Florida
  • Florida Cancer Specialists — Orlando, Florida
  • Florida Cancer Specialists — Sarasota, Florida
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) o…

Sponsor: Genmab
NCT ID: NCT05579366
Sites in Florida:
  • USOR Florida Cancer Specialists South — Fort Myers, Florida
  • USOR Florida Cancer Specialists North — St. Petersburg, Florida
  • USOR Florida Cancer Specialists East — West Palm Beach, Florida
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…

Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in Florida:
  • University of Miami - Sylvester Comprehensive Cancer Center — Miami, Florida
  • Advent Health — Orlando, Florida
  • Florida Cancer Specialists South — Port Charlotte, Florida
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311/BNT324 in subjects with advanced solid tumors.

Sponsor: DualityBio Inc.
NCT ID: NCT05914116
Sites in Florida:
  • Research Site 118 — Celebration, Florida
  • Research Site 127 — Margate, Florida
  • Research Site 137 — Orlando, Florida
  • Research Site 101 — Plantation, Florida
  • Research Site 109 — Tamarac, Florida
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

Study STX-478-101 (LY4064809) is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 (LY4064809) in participants with advanced solid tumors with…

Sponsor: Eli Lilly and Company
NCT ID: NCT05768139
Sites in Florida:
  • Florida Cancer Specialists ORLANDO/DDU — Lake Mary, Florida
  • Moffitt Cancer Center — Tampa, Florida
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

The purpose of this study is to find out whether the study drug, LY3537982, is safe and effective in cancer patients who have a specific genetic mutation (KRAS G12C). Patients must have already received or were not able to tolerate the sta…

Sponsor: Eli Lilly and Company
NCT ID: NCT04956640
Sites in Florida:
  • AdventHealth Orlando — Orlando, Florida
  • Florida Cancer Specialists — Sarasota, Florida
View on ClinicalTrials.gov →

Showing 25 of 94 trials with sites in Florida. See all ovarian cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-05-25